New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
12:07 EDTTHRX, WPRT, HUM, DG, OCN, ELNOptions with increasing implied volatility: THRX WPRT HUM DG OCN ELN
News For THRX;WPRT;HUM;DG;OCN;ELN From The Last 14 Days
Check below for free stories on THRX;WPRT;HUM;DG;OCN;ELN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
10:52 EDTHUMWellCare issues largely company-specific, says UBS
UBS notes that aside from WellCare (WCG), which attributed its lowered guidance to the start-up of its Florida MMA program and other issues, that Centene (CNC), WellPoint (WLP), UnitedHealth (UNH) and Humana (HUM) are the leaders in Medicaid in the state. However, the firm believes a majority of WellCare's issues appear company specific and UBS views any weakness in UnitedHealth, WellPoint, Aetna (AET), or Cigna (CI) as opportunity to buy those four stocks, on all of which it has Buy ratings.
July 24, 2014
10:03 EDTTHRXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:32 EDTTHRXTheravance downgraded at BofA/Merrill
Subscribe for More Information
06:50 EDTHUMConsumers received $9B in refunds from health insurers, The Hill says
Subscribe for More Information
06:07 EDTTHRXTheravance downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
July 22, 2014
13:46 EDTHUMCourt upholds Obamacare subsidies, NY Times says
Subscribe for More Information
10:43 EDTHUMAppeals court bars subsidies in health care law
A three-judge panel of the D.C. Circuit Court of Appeals struck down part of President Obama's healthcare law by siding today with plaintiffs who argued that the law barred the government from giving subsidies to people in states that chose not to set up their own insurance marketplaces. The appeals court stated, "Because we conclude that the ACA unambiguously restricts the section 36B subsidy to insurance purchased on Exchanges 'established by the State,' we reverse the district court and vacate the IRSís regulation." Twenty-seven states decided against setting up marketplaces, and another nine states partially opted out, according to the Washington Post.
July 21, 2014
16:00 EDTDGOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
13:23 EDTDGHigh option volume stocks: RFMD LCI MR PII DG CTRL
Subscribe for More Information
July 16, 2014
17:14 EDTDGIcahn: Dollar General CEO leaving may impact possible deal with Family Dollar
Subscribe for More Information
17:08 EDTDGIcahn disappointed Dollar General CEO leaving
Subscribe for More Information
15:54 EDTDGPeltz says 'not satisfied' with performance at Family Dollar
Subscribe for More Information
07:07 EDTOCNOcwen Financial creates Community Advisory Council
Ocwen Financial announced the creation of a Community Advisory Council. The Council will provide a forum for Ocwen leaders and community advocates to share ideas, discuss policy issues and collaboratively identify opportunities for Ocwen to have a positive impact on local communities, particularly those hit hardest by the economic downturn. The Council will work with Ocwen to consider issues such as principal reduction modifications for families with underwater mortgages; reducing urban blight; helping communities of color that have been hardest hit by the mortgage crisis; and improving language access to borrowers with limited English proficiency. The Council will be chaired by Ronald Faris, president and CEO of Ocwen, and will initially consist of 15 leading non-profit community advocates and housing counseling agencies from around the country. Other members may be added to the Council in the future.
05:38 EDTTHRXGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.
July 14, 2014
16:17 EDTOCNOcwen Financial announces repurchase from WL Ross & Co. Managed Funds
Ocwen Financial announced that earlier the 62,000 outstanding shares of its Series A Perpetual Convertible Preferred Stock were converted into common stock and immediately repurchased and cancelled. "This transaction is in addition to our strategy to repurchase shares of common stock roughly equivalent to our prior period earnings pursuant to our previously announced share repurchase program," commented Bill Erbey, Ocwen's Executive Chairman.
16:15 EDTHUMHumana, Tenet sign new multi-year national agreement
Subscribe for More Information
07:22 EDTHUMHealthcare Education Associates to hold a conference
4th Annual RISE California Summit to be held in San Diego on July 13-15.
07:06 EDTOCNAltisource Solutions pullback a buying opportunity, says Piper Jaffray
Piper Jaffray views the recent pullback in shares of Altisource Solutions (ASPS) as a buying opportunity. Piper says shares recently sold off 10% due to some concerns around Ocwen Financial's (OCN) Homeward origination business joining Ellie Mae's Total Quality Loan Program. Piper believes Altisource's relationship with Ocwen remains "very strong" and it reiterates an Overweight rating on the stock with a $156 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use